The current technologies and assays used in drug discovery do not accurately represent human disease, leading to the lack of predictability of medicines discovery.
This means packages of data generated may have weaknesses that cause the wrong decisions to be made about which medicines to progress and how to progress them.
It can decrease company valuations, lower the chance of investment and lead to high failure rates in clinical trials.
We are developing novel technologies, analytics, and workflows to generate data to help support decision-making.
